Epstein-Barr virus induced adoptive T-Cell therapy - EutilexAlternative Names: EBV-induced Natural T cell; EBViNT
Latest Information Update: 19 Jan 2017
At a glance
- Originator Eutilex
- Class Cell therapies
- Mechanism of Action CD137 antigen modulators; Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer